Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/18—Sulfonamides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/06—Antiarrhythmics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• This invention relates to the field of medical treatment methods, including intravenous methods of administration of drugs to a subject.
• Glyburide (also known as, e.g., glibenclamide) is a sulfonylurea drug used in treating diabetes.
• the systematic name of glyburide is 5-chloro-N-(4-[N-(cyclohexylcarbamoyl) sulfamoyl]phenethyl)-2-methoxybenzamide.
• Glyburide preferentially binds to and affects the sulfonylurea receptor 1 (SURl) but at higher concentrations also binds to and affects the sulfonylurea receptor 2 (SUR2).
• Glyburide has been suggested as a therapy for acute stroke (ischemic and hemorrhagic), traumatic brain injury (TBI), spinal cord injury (SCI), myocardial infarction (MI), shock (including hemorrhagic shock), organ ischemia, and ventricular arrhythmias.
• novel methods of administering glyburide, or other drug are disclosed.
• the novel methods disclosed herein include methods of administering glyburide, or other drug, over periods of more than an hour to a subject, and preferably over periods of many hours (e.g., about 72 hours or about 96 hours or about 120 hours), and in particular include intravenous methods of
• glyburide or other drug
• the methods disclosed herein may be useful for treating a subject in need of treatment for, e.g., acute stroke (ischemic and
• intravenous glyburide is preferable as targeted glyburide plasma levels can be more quickly and reliably reached and maintained.
• the methods disclosed herein provide rapid achievement of therapeutic levels of glyburide, or other drug, following initiation of drug administration, and also provide for maintenance of therapeutic levels of glyburide, or other drug, over an extended period of time, e.g., for about 72 hours or about 96 hours or about 120 hours),.
• the methods disclosed herein provide rapid achievement of therapeutic drug levels, maintenance of therapeutic drug levels for an extended period of time, and further avoid excessive levels of drug and so avoid possible drug side-effects.
• Embodiments of the methods of administering glyburide, or other drug, to a subject include intravenous administration of a bolus of glyburide, or other drug, followed (either substantially immediately, or after a delay after completion of the bolus administration) by a continuous infusion of glyburide, or other drug.
• Further embodiments of the methods of administering glyburide, or other drug, to a subject include intravenous administration of a first bolus of glyburide, or other drug, followed (either substantially immediately, or after a delay after completion of the bolus administration) by a continuous infusion of glyburide, or other drug, followed by a second bolus of glyburide, or other drug.
• a second infusion may follow a second bolus.
• multiple blouses and multiple infusions may be administered to a subject.
• the administration of glyburide to a subject extends over periods of more than an hour to a subject; in particular embodiments, the methods of administration of glyburide to a subject are intravenous methods of administration of glyburide to a subject where the administration extends over periods of more than an hour.
• administration of glyburide, or other drug extends over periods of more than about 72 hours.
• administration of glyburide, or other drug extends over periods of more than about 10 hours, or more than about 20 hours, or more than about 30 hours, or more than about 40 hours, or more than about 50 hours, or more than about 60 hours, or more than about 70 hours.
• the methods of administration include administration of glyburide in a bolus injection to a subject, where the bolus injection is administered to the patient over a period of time of about 3 minutes or less; and where the bolus administration is followed by a continuous infusion of glyburide.
• the bolus is followed substantially immediately by the initiation of the continuous infusion (e.g., the continuous infusion commences less than one hour, or less than 30 minutes, or less than 10 minutes, or less than 5 minutes, or less than 3 minutes, or less than 2 minutes, or less than 1 minute, after the completion of the bolus administration).
• the methods of administration include administration of glyburide in a bolus injection to a subject, where the bolus injection is administered to the patient over a period of time of about 3 minutes or less; and where the bolus administration is followed by a continuous infusion of glyburide, or other drug, and by one or more further bolus injections of glyburide, or other drug.
• a second bolus injection is administered substantially immediately after the completion of the continuous infusion (e.g., the second bolus administration commences less than one hour, or less than 30 minutes, or less than 10 minutes, or less than 5 minutes, or less than 3 minutes, or less than 2 minutes, or less than 1 minute, after the completion of the continuous infusion).
• a second continuous infusion may begin
• substantially immediately after the completion of the second bolus injection, or a second continuous infusion may begin after an extended period of time after the completion of the first continuous infusion.
• a third bolus injection may begin after the completion of the second continuous infusion, and may begin either substantially immediately after the completion of the second continuous infusion, or may begin after an extended period of time after the completion of the second continuous infusion.
• a fourth, or fifth, or other further bolus injection, and/or further continuous infusion may be administered, either substantially immediately, or after an extended period of time.
• multiple bolus injections of glyburide, or other drug may be administered to a subject, without an intervening continuous infusion of glyburide, or other drug.
• multiple continuous infusions of glyburide, or other drug may be administered to a subject, without an intervening bolus injection of glyburide, or other drug.
• Such multiple bolus injections, or continuous infusions, or combinations thereof may be administered substantially immediately after the previous injection or infusion, or may be administered after an extended period of time after the previous injection or infusion.
• a continuous infusion provides the administration of glyburide, or other drug, over an extended period of time, where an extended period of time may be a period of time measured in minutes (e.g., a few or several or many minutes), or measured in hours (e.g., a few or several or many hours), or measured in days (e.g., a few or several or many days).
• an extended period of time may be a period of time measured in minutes (e.g., a few or several or many minutes), or measured in hours (e.g., a few or several or many hours), or measured in days (e.g., a few or several or many days).
• the concentration of glyburide, or other drug is higher in the formulation administered by bolus injection than the concentration of glyburide, or other drug, in the formulation administered by continuous infusion.
• Applicant discloses herein that the blood levels of glyburide in human subjects typically reaches apeak level some hours following initiation of glyburide administration (e.g., after initiation of a bolus injection of glyburide followed by a continuous infusion of glyburide to the subject).
• Applicant discloses herein a 3 phase dosing regimen suitable for overcoming the dip in glyburide plasma levels which occurs several hours following the initiation of glyburide administration.
• a 3 phase dosing regimen comprises: (a) a bolus followed by a second bolus followed by a continuous infusion
• Rate 1 refers to a first rate
• Rate 2 refers to a second rate, of administration of glyburide, or other drug, typically measured as, e.g., micrograms per hour ⁇ g/hr).
• administration of glyburide, or other drug is provided by 4 or more phases in the dosing regimen where multiple boluses and/or multiple infusion rates can be used.
• multiple rates and durations of administration are also provided (e.g., a Rate 1, Rate 2, Rate 3, Rate 4, etc.; and time periods A, B, C, etc.).
• Rate 1 may vary between about 15 ⁇ g/hr and about 200 - 300 ⁇ g/hr (e.g., between about 16.7 ⁇ g/hr and 250 ⁇ g/hr), and Rate 2 may vary between about 15 ⁇ g/hr and about 200 - 300 ⁇ g/ r (e.g., between 16.7 and 250 ⁇ g/hr).
• time period A may vary from about 1 to about 10 hours, or from about 1 to about 20 hours.
• the total amount of glyburide, or other drug, delivered to the subject is the sum of the amount delivered by the bolus injection(s) plus the amount delivered during the continuous infusion.
• the amount of glyburide, or other drug, delivered to the subject during continuous infusion is calculated by multiplying the Rate times the time period (e.g., Rate 1 X time period A).
• the daily dose (the dose over a 24 hour period, for example, the dose for the first 24 hours of glyburide administration) may be determined as follows: first Bolus + Rate 1 x A + Rate 2 x (24-A).
• the dose for the first 24 hours will be less than about 6 mg, or less than about 5 mg, or less than about 4 mg, and preferably may be less than about 3.5 - 4 mg, or less than about 3.13 mg or less than about 3 mg.
• the total amount of glyburide administered to the subject per day be less than about 10 mg, or more preferably less than about 8 mg, or more preferably less than about 6 mg, and still more preferably less than about 5 mg, or yet still more preferably less than about 4 mg, or even more preferably less than about 3 mg of glyburide per day.
• a bolus of about 125 - 150 ⁇ g, e.g., about 130 ⁇ g, of glyburide is administered to a subject followed by a continuous infusion of about 150 - 175 ⁇ g/hr, e.g., about 163 ⁇ g/hr, of glyburide for about 6 hours and then a further continuous infusion of about 100 - 125 ⁇ g/hr, e.g. about 112 ⁇ g/hr, glyburide is administered for about 50 - 75 hours, e.g. about 66 hours, for a total dosing period of about 72 hours.
• the total daily dose of glyburide on Day 1, Day 2 and Day 3 may be about 3-4 mg, 2.5 - 3 mg, and 2.5 - 3 mg; e.g., about 3 mg, 2.5 mg, and 2.5 mg, respectively; or about 3.12 mg, 2.69 mg, and 2.69 mg respectively.
• a bolus of glyburide, or other drug is administered, and the bolus is followed by a continuous infusion of glyburide, or other drug, and then a further bolus or further boluses is/are administered, effective to raise early plasma levels of glyburide, or other drug, to desired levels.
• such an embodiment of the methods disclosed herein would include administration of a bolus of 125 - 150 ⁇ g, e.g., about 130 ⁇ g, glyburide followed by a continuous infusion of 100 - 125 ⁇ g/hr, e.g., about 112 ⁇ g/hr of glyburide, with a second glyburide bolus of 125 - 150 ⁇ g, e.g., about 130 ⁇ g, administered at hour 1, 2, or 3.
• a bolus of 125 - 150 ⁇ g e.g., about 130 ⁇ g
• glyburide e.g., about 130 ⁇ g
• further boluses may be administered as well.
• Applicant discloses herein a method of administering glyburide, or other drug, to a subject, comprising: (a) a bolus administration of glyburide, or other drug; (b) a first continuous infusion administration of glyburide, or other drug after said bolus
• the bolus is a bolus of about 125 - 150 ⁇ g, e.g., about 130 ⁇ g, of glyburide, and the bolus is followed by a continuous infusion of about 150-175 ⁇ g/hr, e.g., about 163 ⁇ g/hr of glyburide for about 6 hours; and then a further
• glyburide continuous infusion of about 100 - 125 ⁇ g/hr, e.g., about 112 ⁇ g/rlr glyburide is administered to the subject for about 66 hours, for a total period of glyburide administration of about 72 hours.
• the total daily dose of glyburide on Day 1, Day 2 and Day 3 is thus about 3 mg, 2.5 mg, and 2.5 mg respectively; or about 3.12 mg, 2.69 mg, and 2.69 mg respectively.
• Dosing of glyburide, or other drug may be determined as a function of a subject's weight, or age, or gender, or height, or body surface area, or a combination of one or more of these, and the rates and bolus may be expressed as a function of one or more of these measures or methods of dosing.
• the methods disclosed herein provide advantages for treating subjects in need of a fairly steady amount of glyburide introduced rapidly and maintained over an extended period of time (e.g., for up to about 72 hours). For example, where a subject has suffered a stroke, or traumatic brain or spinal cord injury, rapid achievement of therapeutic levels of glyburide may be important to a successful therapeutic outcome; in addition, maintenance of such therapeutic levels may likewise be important to a successful therapeutic outcome; however, it may also be important to prevent sustained levels of glyburide that are too high for the subject (e.g., to avoid hypoglycemia, extensive action of glyburide on the SUR2 receptor, or other complications).
• Subject in need of such treatments may include, for example, subjects suffering from acute stroke (ischemic and hemorrhagic), traumatic brain injury (TBI), spinal cord injury (SCI), myocardial infarction (MI), shock (including hemorrhagic shock), organ ischemia, and ventricular arrhythmias.
• glyburide in addition to glyburide, may be administered to a subject according to the methods disclosed herein. Administration of such other drugs may be particularly advantageous where the other drug has a pharmacokinetic profile similar to that of glyburide, as disclosed herein, or shares some of the pharmacokinetic properties of glyburide.
• Applicants have discovered that it is preferable to avoid contact of a glyburide solution with polyvinyl chloride (PVC), as Applicants have discovered that the concentration of glyburide is reduced in glyburide solutions placed in contact with PVC.
• Applicants have invented methods to minimize such reduction of the concentration of glyburide is reduced in glyburide solutions placed in contact with PVC, and have invented methods of administration of glyburide which avoid contact of glyburide solutions with PVC.
• PVC polyvinyl chloride
• Applicants have discovered that use of polyethylene bags, tubing, and filters, or polyethylene-coated bags and tubing, is preferred for the administration of glyburide solutions over the use of PVC-containing bags, tubing and filters.
• Applicants disclose herein methods of preparing a container or device used in the administration of glyburide, e.g., in the administration of a therapeutic glyburide solution to a patient in need of such a therapeutic solution, are provided herein.
• Such methods of preparing a container or device such as preparing a container, tube, and/or filter, comprise contacting a container, a tube, or a filter with a glyburide flushing solution.
• Such methods may include, for example, flushing a container, tube and/or filter with said glyburide flushing solution prior to its use in the administration of glyburide; the flushing may include flushing with at least about 50 mL, or at least about 70 mL, or more of the glyburide flushing solution.
• a glyburide flushing solution may have a glyburide concentration of at least about 2 ⁇ g/mL of glyburide, or about 2 ⁇ to about 8 ⁇ , of glyburide, or about 5 to 6 ⁇ g/mL of glyburide, or greater concentrations of glyburide.
• Such methods include use of containers and devices, including bags, tubes, and filters which may have polyvinyl chloride (PVC) surfaces that may contact said glyburide therapeutic solution.
• PVC polyvinyl chloride
• Applicants disclose herein methods of administering a glyburide therapeutic solution wherein a container, a tube, and/or a filter is contacted (e.g., flushed) with a glyburide flushing solution prior to use of the container, tube, or filter in the administration of said glyburide therapeutic solution.
• the flushing may be flushing with at least 50 mL, or about 70 mL, or more, of the glyburide flushing solution.
• the glyburide flushing solution may have a glyburide concentration of at least about 2 ⁇ g/mL, or about 2 to about 8 ⁇ g/mL, or more of glyburide.
• the surfaces of containers, tubes, and/or a filters used for the administration of a glyburide therapeutic solution are preferably made of one or more materials other than polyvinyl chloride (PVC), for example, with polyethylene, in order to avoid contact of the glyburide therapeutic solution with PVC.
• PVC polyvinyl chloride
• Applicants further provide methods of administering glyburide therapeutic solutions, in which a high concentration glyburide solution (e.g., at least about 10 ⁇ g/mL glyburide) is filtered and then diluted to provide a glyburide therapeutic solution (typically of lower glyburide concentration than the high concentration glyburide solution), and administering the glyburide therapeutic solution using delivery means made of one or more materials other than polyvinyl chloride (PVC), such as, e.g., polyethylene.
• PVC polyvinyl chloride
• a high concentration glyburide solution may have a glyburide concentration of between about 0.5 mg/mL glyburide and about 1 mg/mL glyburide, and may have a glyburide concentration of at least about 1 mg/mL glyburide.
• the glyburide therapeutic solution may be stored after filtering and prior to administration; in embodiments, the filtered glyburide therapeutic solution is stored within a container having an inner surface in contact with said glyburide therapeutic solution, wherein said container inner surface is made from one or more materials other than polyvinyl chloride (PVC), such as, e.g., polyethylene.
• PVC polyvinyl chloride
• solutions discussed herein such as glyburide solutions, and including without limitation, glyburide therapeutic solutions, glyburide flushing solutions, high concentration glyburide solutions, and other solutions may be filtered, and that such filtering is preferably sterile filtering, effective to provide sterile solutions suitable for administration to a patient.
• sterile filtration may include, for example, filtration through a sterile 0.2 micron filter, or other sterile filter suitable for use in providing sterile filtered solutions.
• Fig. 1 Mean plasma glyburide concentrations for 0.4 mg/day glyburide.
• Fig. 2 Mean plasma glyburide concentrations for 3 mg/day glyburide.
• Fig. 3 Mean plasma glyburide concentrations for 6 mg/day glyburide.
• Fig. 4 Mean plasma glyburide concentrations for 10 mg/day glyburide.
• Fig. 5 Median blood glucose levels for placebo (0 mg/day glyburide), 0.4 mg/day glyburide, and 3 mg/day glyburide.
• patient refers to human patients, volunteers, subjects, and the like.
• ALT is an acronym and means alanine transaminase.
• AST is an acronym and means aspartate transaminase.
• dose refers to the amount of glyburide administered to a subject.
• a dose may be described in terms of the grams of glyburide, or in terms of the weight/volume of diluent administered to the subject (e.g., milligrams per milliliter: mg/mL; micrograms per milliLiter: ⁇ g/mL; nanograms per milliliter: ng/mL; etc.).
• the glyburide may be in water, such as sterile water for injection or other suitable water; in saline; in sugar solution; or in any pharmaceutically acceptable solution, which may include any other pharmaceutically acceptable drugs, excipients, osmoticants, diluents, buffers, preservatives, or other compounds or additives suitable for use in a fluid for injection.
• C max indicates the maximum concentration, in the blood, of glyburide.
• AUC indicates area under the curve (the integral of the plasma concentration of the drug over an interval of time), and is used as a measure of the total amount of glyburide, or other drug, to which the subject is exposed by the drug administration.
• the term "clearance” refers to the loss of glyburide, or other drug, from the blood of the patient. Clearance refers to a fraction of a (theoretical) volume of plasma from which the drug has been completely removed, per unit of time. Clearance may be measured, for example, in liters per hour (L/h), in milliters per minute (mL/min).
• volume of distribution refers to volume of distribution, a term known to those of skill in the art, which refers to the volume (or potential volume) into which a drug, such as glyburide, would be distributed in a subject's body if it were distributed homogeneously (i.e., at the same concentration throughout that volume). Volume of distribution is typically measured in liters or liters per kilogram (L or L/kg).
• Beta provides a measure of the rate of transport of a drug, such as glyburide, into or out of the blood and tissue of a subject.
• t 0 or "t zer o" refers to the initial time, from which further time measurements are taken.
• the time t 0 is the time at which administration commences.
• This initial time, the time to, is the time at which administration commences whether the administration is bolus
• t ⁇ refers to the half-life, typically measured in hours (h), minutes (min) or seconds (s), of a drug that has been administered to a subject.
• the time to which the level (e.g., concentration) of glyburide or other drug (in the blood of a subject to which glyburide or other drug has been administered) drops to half its previous value is the t ⁇ i2 for that subject.
• t max refers to the time to which the level (typically
• concentration in the blood concentration in the blood of a drug that has been administered to a subject reaches its maximum level.
• the time to which the level (e.g., concentration) of glyburide or other drug (in the blood of a subject to which glyburide or other drug has been administered) reaches its maximum after initial administration is the t max for that subject.
• bolus refers to administration of glyburide or other drug in a single injection that lasts for a relatively short period of time. As used herein, a bolus lasts for a period of time of about 3 minutes or less. A bolus injection may be an injection of a relatively high dose or concentration of drug.
• continuous refers to administration of glyburide or other drug in an injection that lasts for an extended period of time.
• a continuous injection may be an injection of a moderate dose or concentration of drug, or of a relatively low dose or concentration of drug.
• infusion is often used with continuous injection; as used herein, “continuous injection” and “continuous infusion” both equally refer to the intravenous administration of a drug, such as glyburide, to a patient over an extended period of time.
• an extended period of time refers to a period of time that is longer than one or two or three minutes.
• an extended period of time may be a period of about 10 minutes, or about 20 minutes, or about 30 minutes, or about 40 minutes, or about 50 minutes, or more.
• an extended period of time may be a period of about one hour, or about 2 hours, or about 3 hours, or about 4 hours, or about 5 hours, or about 6 hours, or about 7 hours, or about 8 hours, or about 9 hours, or more.
• an extended period of time may be a period of about 10 hours, or about 12 hours, or about 15 hours, or about 20 hours, or about 25 hours, or about 30 hours, or about 40 hours, or about 44 hours, or about 48 hours, or more. It will be understood that an extended period of time may also be a period of about one day, or about two days, or about three days, or about four days, or about five days, or more.
• substantially immediately refers to a period of time that is less than about one hour, or less than 30 minutes, or less than 10 minutes, or less than 5 minutes, or less than 3 minutes, or less than 2 minutes, or less than 1 minute, after a previous event or time period.
• placebo refers to an ostensibly pharmaceutical formulation which lacks a pharmaceutically active ingredient, or lacks the particular pharmaceutical ingredient of interest in a particular study.
• placebo refers to a formulation identical to the formulation given to test subjects but lacking glyburide (e.g., including mannitol and NaoH, but not including glyburide).
• a placebo may include inert compounds, and any pharmaceutically acceptable compound which may be found in a medicament, so long as it lacks a pharmaceutically active ingredient (as determined with respect to the pharmaceutical ingredient to which it is to be compared).
• BG blood glucose
• PRN means prescribed as needed.
• time periods may be indicated as hours (e.g., H10 indicates at hour 10, or 10 hours following initiation of treatment) or days (e.g., D2 indicates day 2, or the second day following initiation of treatment).
• D5W indicates water with 5grams (g) of dextrose per 100 milliliters (mL) of water.
• RP-1 127 refers to glyburide, or to glyburide formulations. Applicant has performed experiments including the administration of glyburide and of placebo to subjects. Results of these experiments are disclosed in the following examples.
• glyburide concentration is reduced by contact with to poly- vinyl chloride (PVC).
• PVC poly- vinyl chloride
• glyburide concentration is reduced when a glyburide-containing solution is passed through PVC tubing, or stored in a PVC bag.
• glyburide concentration is reduced when glyburide-containing solutions are stored in PVC bags at glyburide concentrations below 10 ⁇ g/mL.
• PVC poly- vinyl chloride
• glyburide At 10 ⁇ g/mL glyburide we were able to use a standard PVC bag (but not PVC tubing) with an acceptable amount of loss of glyburide (e.g., loss presumably due to adsorption to PVC).
• glyburide concentration in a glyburide-containing solution is reduced by passage though a filter, such as through a 0.2 micron in-line filter.
• glyburide was administered through low sorbing polyethylene (PE)-lined tubing with an inline filter that had been flushed according to a predetermined flushing protocol (see below) designed to ensure that the concentration of glyburide was reduced by no more than about 10%.
• PE polyethylene
• a predetermined flushing protocol e.g. 0.4 mg/day, 3 mg/day and 6 mg/day (in which the glyburide concentration was less than 10 ⁇ g/mL)
• PVC-free bags we used for the 10 mg/day dose (in which the glyburide concentration was 10 ⁇ g/mL), we used PVC bags.
• a PALL Pharmassure 0.2 micron filter HP 1002 (Pall Life Sciences, 600 South Wagner Road, Ann Arbor, MI 48103) that had been flushed with the glyburide solution to be administered (ranging from about 2-3 ⁇ g/mL to about 50 - 75 ⁇ g/mL, e.g., ranging from about 2.5 ⁇ g/mL to about 60 ⁇ g/mL (for example, from 2.48 ⁇ g/mL to about 62.00 ⁇ g/mL) prior to use for injection.
• HP 1002 Pall Life Sciences, 600 South Wagner Road, Ann Arbor, MI 48103
• the PVC free bag used was the B Braun EXCEL L8000 (B. Braun Medical Inc., 824 Twelfth Avenue, Bethlehem, PA 18018.
• the PVC bag used was the Viaflex 1 ,000 mL 2B 1324X (Baxter, One Baxter Parkway, Deerfield, IL 60015-4625).
• the Careiusion 2260-0500 (CareFusion Corporation, 3750 Torrey View Court, San Diego, CA 92130) low sorbing administration set attached to an Carefusion 20350E (CareFusion Corporation, 3750 Torrey View Court, San Diego, CA 92130) low sorbing extension set with a 0.2 micron low protein binding filter was used for administering glyburide at 10 ⁇ / ⁇ , concentration.
• the Carefusion 10010454 (CareFusion Corporation, 3750 Torrey View Court, San Diego, CA 92130) low sorbing administration set with built in 0.2 micron filter was used for administration of glyburide at concentrations below about 10 ⁇ g/mL.
• a glyburide flushing solution has a glyburide concentration of at least about 2 ⁇ g/mL, or about 2- 8 ⁇ g/mL, or about 5 - 6 ⁇ g/mL, or about 10 ⁇ g/mL, or greater.
• the catheter used was a BD Nexiva catheter (BD, 1 Becton Drive, Franklin
• a 0.2 micron filter for example the Millex 0.22um Durapore PVDF filter SLGV033RS or SLGVM33RS (Millipore, 290 Concord Road, Billerica, MA 01821), or the PALL 0.2 micron filter, HP 1002
• the filtered material was diluted into a PVC-free bag (for example, the B Braun EXCEL L8000).
• the filtered glyburide solution in the PVC-free bag is ready for administration to a patient through unfiltered polyethylene lined tubing (for example the Carefusion 2260-0500 or Carefusion C20014) or through polyethylene lined tubing that is substantially PVC-free i.e. has only a short section of PVC, for example the Hospira 11993-78 (275 North Field Drive, Lake Forest, Illinois 60045).
• the tubing may optionally be flushed with one flush of about 50 mL to about 75 mL (e.g., about 70 mL) of glyburide flushing solution (glyburide concentration of at least about 2 ⁇ g/mL, or about 2- 8 ⁇ g/mL, or about 5 - 6 ⁇ g/mL, or about 10 ⁇ g/mL, or greater).
• glyburide flushing solution glyburide concentration of at least about 2 ⁇ g/mL, or about 2- 8 ⁇ g/mL, or about 5 - 6 ⁇ g/mL, or about 10 ⁇ g/mL, or greater.
• Glyburide has been administered to two patients with such a procedure.
• the SLGVM33RS syringe filter and the 2260-0500 administration set with 6 x C20014 extension sets attached to it were used.
• the SLGV033RS syringe filter and the Hospira 1 1993-78 administration set with 6 x C20014 extension sets attached to it were used.
• a glyburide solution that includes a glyburide concentration that is sufficiently high (e.g., at least about 10 ⁇ g/mL, preferably between about 0.5 and about 1 mg/mL and even more preferably about 1 mg/mL or greater) so that the filtering process does not significantly decrease the glyburide concentration, and then diluting the solution into a PVC-free bag to provide sufficient volume of solution to allow administration through a standard intravenous (IV) pump, then administering the solution through a filter-less polyethylene lined administration set (or a set that is mostly polyethylene lined with a short PVC section) are effective to provide clinically effective concentrations of glyburide for
• Patients in need of glyburide treatment include patients suffering from stroke, such as acute stroke (ischemic and
• hemorrhagic traumatic brain injury
• TBI spinal cord injury
• SI spinal cord injury
• MI myocardial infarction
• shock including hemorrhagic shock
• organ ischemia ventricular arrhythmias
• ischemic injury hypoxia/ischemia; and other injuries, conditions, and disorders.
• BD catheter containing BD VialonTM material was used for both patients (BD, 1 Becton Drive, Franklin Lakes, NJ USA 07417); the catheter was not flushed or tested.
• Pharmacokinetic parameters of RP-1127 were independent of dose, weight, height, body surface area, gender and age.
• Figure 1 shows the mean plasma glyburide concentrations measured in patients receiving 0.4 mg/day of glyburide.
• the mean steady state glyburide concentration (Css) at 0.4 mg/day was 3.8 ng/mL, and the maximum glyburide concentration (Cmax) was 7.2 ng/mL, which occurred at hour 72.
• glyburide plasma levels were reduced by 54% (from 4.4 ng/mL to 2.0 ng/mL). Glyburide plasma levels for 50% of the patients were below the limits of detection (0.5 ng/mL) by hour 76 and in 100% of patients by hour 96.
• Figure 2 shows the mean plasma glyburide concentrations measured in patients receiving 3 mg/day of glyburide.
• mean Css was 25.3 ng/mL and Cmax (of all individual subjects) was 50.7 ng/mL, which occurred in one patient at hour 48.
• mean glyburide plasma levels were reduced by 57% (from 27.3 ng/mL to 11.9 ng/mL).
• Glyburide plasma levels were below the limits of detection in 50% of the subjects by hour 84 and in 100% of patients by hour 96.
• Figure 3 shows the mean plasma glyburide concentrations measured in patients receiving 6 mg/day of glyburide. Dosing was stopped early, at around 32 hours due to the hypoglycemic effect of the drug.
• Figure 4 shows the mean plasma glyburide concentrations measured in patients receiving 10 mg/day of glyburide. Dosing was stopped early, at around 24 hours due to the hypoglycemic effect of the drug. Blood Glucose / Hypoglycemia Data
• Figure 5 shows the median blood glucose levels in patients receiving placebo (no glyburide), 0.4 mg/day glyburide, and 3 mg/day glyburide.
• placebo no glyburide
• 0.4 mg/day dose had a very minor but visible effect on BG and the 3.0 mg/day dose had a more pronounced effect, without hypoglycemia (prolonged BG ⁇ 70 mg/dL or signs/symptoms of hypoglycemia e.g.
• subject had classic symptoms of hypoglycemia but was always alert, oriented and conversant. Subject was also able to consume all food and liquids provided.
• BG ⁇ 70 mg/dL (68 mg/dL) and the glyburide plasma level was 64 ng/mL.
• the subject receiving 433 ⁇ g bolus plus 10 mg/day glyburide experienced blood glucose levels in the range 63 mg/dL - 81 mg/dL from HI to H8, which reduced in the 52-53 mg/dL range during H12— H22.
• the subject was treated PRN throughout this time with the following: glucose gel, yogurt, apple juice, a bagel and peanut butter. At hour 22, the morning serum glucose below 50 mg/dL at which point dosing was suspended. During this episode, subject had classic symptoms of hypoglycemia but was always alert, oriented and conversant. Subject was also able to consume all food and liquids provided.
• BG was below 70 mg/dL and the glyburide plasma level was 57.94 ng/mL.
• Applicant notes that severe hypoglycemia occurred at 6 mg/day of glyburide and 10 mg/day of glyburide delivered as continuous infusions (250 ⁇ g/hr and 17 ⁇ g/hr). It appears that glyburide levels of above about 50 ng/mL, and probably in the range about 58-64 ng/mL or above are sufficient to cause hypoglycemia that is clinically relevant and/or refractory to treatment. It was surprisingly difficult to treat the hypoglycemia caused by the continuous infusion at high doses (6 and 10 mg/day) while maintaining glyburide administration.
• hypoglycemia for example, when treating a subject suffering from acute stroke (ischemic and hemorrhagic), traumatic brain injury (TBI), spinal cord injury (SCI), myocardial infarction (MI), shock (including hemorrhagic shock), organ ischemia, and ventricular arrhythmias.
• plasma levels of glyburide of less than about 50 ng/mL are preferred plasma levels, providing the therapeutic benefits of glyburide while avoiding most or all of the deleterious side effects that higher concentrations might cause (e.g., hypoglycemia).
• glyburide levels of about 10 ng/mL to about 20 ng/mL, or of about 20 ng/mL to about 30 ng/mL, or of approximately 25 ng/mL should be targeted, it being understood that by doing so, a wide concentration range (up to approximately 50 ng/mL at peak) of glyburide in the blood stream can be expected, at least for short periods of time.
• intravenous glyburide is likely to be administered e.g. acute stroke (ischemic and hemorrhagic), traumatic brain injury (TBI), spinal cord injury (SCI), myocardial infarction (MI), shock, organ ischemia, and ventricular arrhythmias
• acute stroke ischemic and hemorrhagic
• TBI traumatic brain injury
• SCI spinal cord injury
• MI myocardial infarction
• shock organ ischemia
• hypoglycemia can have negative effects, thus it is preferably to treat patients with doses of intravenous glyburide that will not cause extended or clinically significant hypoglycemia.
• glycogen in hepatocytes is also associated with elevations in serum aminotransferases and this has been described in poorly controlled diabetes (Sayuk et al. 2007, Chatila et al. 1996). Glycogen deposition in the liver could occur quite quickly and may therefore account, at least in part, for aminotransferase elevations observed with carbohydrate loading. It also seems likely that the hyperinsulinemic effect of glyburide would exacerbate the carbohydrate uptake and conversion to glycogen by the liver.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Epidemiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Diabetes (AREA)
• Biomedical Technology (AREA)
• Hematology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Dermatology (AREA)
• Vascular Medicine (AREA)
• Urology & Nephrology (AREA)
• Obesity (AREA)
• Hospice & Palliative Care (AREA)
• Emergency Medicine (AREA)
• Endocrinology (AREA)
• Psychiatry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Anesthesiology (AREA)
• Medical Preparation Storing Or Oral Administration Devices (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Materials For Medical Uses (AREA)
• Infusion, Injection, And Reservoir Apparatuses (AREA)
• Medicinal Preparation (AREA)

Priority Applications (23)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (2)

Family

ID=45497399

Family Applications (1)

Country Status (7)

Cited By (12)

Families Citing this family (7)

Family Cites Families (16)

• 2011
  • 2011-07-18 EP EP11810231.8A patent/EP2595633A4/en not_active Ceased
  • 2011-07-18 KR KR1020237040323A patent/KR20230165363A/ko not_active Ceased
  • 2011-07-18 JP JP2013520785A patent/JP6188021B2/ja active Active
  • 2011-07-18 EP EP18157269.4A patent/EP3339190A1/en not_active Ceased
  • 2011-07-18 CA CA3225438A patent/CA3225438A1/en active Pending
  • 2011-07-18 CA CA2806069A patent/CA2806069C/en active Active
  • 2011-07-18 CA CA3101711A patent/CA3101711C/en active Active
  • 2011-07-18 WO PCT/US2011/044397 patent/WO2012012347A2/en not_active Ceased
  • 2011-07-18 KR KR1020137004062A patent/KR20130133165A/ko not_active Ceased
  • 2011-07-18 CN CN201810945946.3A patent/CN109172363A/zh active Pending
  • 2011-07-18 KR KR1020177029156A patent/KR101917975B1/ko active Active
  • 2011-07-18 KR KR1020197007606A patent/KR20190031592A/ko not_active Ceased
  • 2011-07-18 US US13/811,037 patent/US8946293B2/en active Active
  • 2011-07-18 CN CN201180044843.6A patent/CN103108637B/zh active Active
  • 2011-07-18 EP EP19178203.6A patent/EP3586850A1/en active Pending
  • 2011-07-18 KR KR1020207012483A patent/KR20200054319A/ko not_active Ceased
  • 2011-07-18 KR KR1020257005414A patent/KR20250026419A/ko active Pending
  • 2011-07-18 KR KR1020217042532A patent/KR20220000943A/ko not_active Ceased
  • 2011-07-18 KR KR1020187032015A patent/KR20180123176A/ko not_active Ceased
• 2014
  • 2014-10-28 US US14/525,992 patent/US9254259B2/en active Active
• 2015
  • 2015-10-08 US US14/878,232 patent/US9561176B2/en active Active
  • 2015-10-29 JP JP2015212868A patent/JP6179574B2/ja active Active
• 2017
  • 2017-02-06 US US15/425,874 patent/US10052280B2/en active Active
  • 2017-03-16 JP JP2017051153A patent/JP6506335B2/ja active Active
  • 2017-08-25 US US15/686,989 patent/US10391053B2/en active Active
• 2018
  • 2018-12-10 JP JP2018230763A patent/JP6795571B2/ja active Active
• 2019
  • 2019-07-02 US US16/459,893 patent/US10786445B2/en active Active
• 2020
  • 2020-02-07 JP JP2020019464A patent/JP2020073595A/ja active Pending
  • 2020-09-24 US US17/030,925 patent/US11559481B2/en active Active
• 2023
  • 2023-01-20 US US18/157,302 patent/US12226521B2/en active Active
• 2025
  • 2025-01-09 US US19/015,309 patent/US20250221924A1/en active Pending

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events